Biotech | August 02, 2021
Bharat Biotech gets WHO prequalification for ROTAVAC 5D
WHO prequalification enables the procurement of ROTAVAC 5D by UN agencies namely UNICEF and PAHO
WHO prequalification enables the procurement of ROTAVAC 5D by UN agencies namely UNICEF and PAHO
The TWYMEEG approval is supported by numerous preclinical and clinical studies, including the Phase 3 TIMES (Trials of IMeglimin for Efficacy and Safety) program managed jointly by both the companies
Bayer Zydus Pharma will continue to operate in core therapies with new products in the pipeline
Researchers observed that a form of vitamin D, known as 25-hydroxyvitamin D3 (Calcifediol), was absorbed faster and better than the same dose of vitamin D.
The facility is expected to be completed in 2024
In animal health, the products will be mainly targeting mastitis and production disorders, gastrointestinal tract diseases, reproductive disorders, ectoparasites, and skin injuries
Presently, IMPCL is manufacturing 656 classical Ayurvedic, 332 Unani and 71 proprietary Ayurvedic medicines for the various diseases spectrum
The company is pursuing specific goals in the areas of science and technology, value chain as well as climate and the environment.
Both the vaccines have been extensively tested by IVRI for safety and potency and have been found to provide 100% protection
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
Subscribe To Our Newsletter & Stay Updated
